Axsome Therapeutics,Inc. (NASDAQ:AXSM) Files An 8-K Results of Operations and Financial Condition
Item2.02.Results of Operations and Financial
Condition
On March7, 2017, Axsome Therapeutics,Inc. (the Company) issued a
press release announcing its financial results for the three
months and fiscal year ended December31, 2016 and an update on
the Companys operations. The Company is furnishing a copy of the
press release, which is attached hereto as Exhibit99.1.
In accordance with General Instruction B.2 of Form8-K, the
information included in this Current Report on Form8-K (including
Exhibit99.1 hereto), shall not be deemed filed for the purposes
of Section18 of the Securities Exchange Act of 1934, as amended
(the Exchange Act), or otherwise subject to the liabilities of
that section, nor shall it be deemed incorporated by reference
into any filing made by the Company under the Exchange Act or
Securities Act of 1933, as amended, except as shall be expressly
set forth by specific reference in such a filing.
Item 9.01. Financial Statements and
Exhibits.
(d) Exhibits.
|
Exhibit Number |
|
Description |
|
99.1 |
Press release dated March7, 2017. |
About Axsome Therapeutics, Inc. (NASDAQ:AXSM)
Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain. It is developing AXS 02 for the treatment of pain in over three conditions, such as complex regional pain syndrome (CRPS); knee osteoarthritis (OA) associated with bone marrow lesions (BMLs), and chronic low back pain (CLBP), associated with type I, or mixed type I and type II Modic changes (MCs). Its product candidate, AXS 05, is a fixed dose combination of dextromethorphan (DM) and bupropion. It is developing AXS 05 for the treatment of over two conditions, such as treatment resistant depression (TRD), and agitation in patients with Alzheimer’s disease (AD). Axsome Therapeutics, Inc. (NASDAQ:AXSM) Recent Trading Information
Axsome Therapeutics, Inc. (NASDAQ:AXSM) closed its last trading session down -0.45 at 4.45 with 44,672 shares trading hands.
